Company profile
Bhang Inc.
OTC: BHNGF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Toronto, ONReports USD
#850 of 1,418 Healthcare companies by revenue29th-percentile growth
EA Score
——FH —DQ —GM —SS 41
v0.1 · 5/100 weight · pillars only
↑ listing tenure, Piotroski F · ↓ Altman-Z, market scale
Methodology →Revenue TTM
$1.4M
Rev growth YoY (TTM)
+68.8%
Net income (FY)
-$3.4M
Employees
14
as of 2026-08-29
Market cap
$20.0k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.3M1.6M CAD2021
Net income-$3.4M-4.2M CAD2021
Operating income-$3.0M-3.7M CAD2021
Total assets$1.7M2.2M CAD2021
Liabilities$2.0M2.5M CAD2021
Equity-$258.9k-328.2k CAD2021
Revenue trend
FY2017 – FY2021 · USD
FY17
FY18
FY19
FY20
FY21
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bhang Inc.’s revenue?
Bhang Inc. booked $1.3M in FY2021 revenue, contracting 17% year over year — slower than 71% of Healthcare companies we track, at a -260.4% net margin.
Peers · Healthcare
Electromedical Technologies, Inc.——Global Roundtable Corporation——Inhibrx Biosciences Inc.28DCertive Solutions Inc.——VistaGen Therapeutics, Inc.46DBaudax Bio, Inc.——Key facts
CEOJohn Graham Simmonds Jr.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, ON
ExchangeOTC: BHNGF
Employees14
IPO date2007-05-16
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.